背景:临床实践指南(CPG)的产生在过去几年中有所增长。尽管如此,这些文献的质量及其对儿童和青少年精神分裂症治疗的建议仍然未知.
目的:评估该人群精神分裂症治疗指南和建议的质量。
方法:通过在EMBASE上的系统搜索,确定了2004年至2020年12月的CPG,MEDLINE,PsycINFO,PubMed,认识论,VHL,全球索引药物和特定的CPG数据库。CPG的质量由三名评审员使用AGREEII独立评估,如果他们在3和6域中得分≥60%,则被认为是高质量的。描述了证据分类系统,使用AGREE-REX对建议质量进行了评估,并对建议进行了比较.
结果:数据库搜索检索到3182个结果;筛选了2030个,选择了29个用于全文阅读。选择了四个指南进行提取。在AGREEII评估中,两个CPG被认为是高质量的。我们描述了每个治疗阶段的共同商定建议。在所有治疗阶段都描述了药理学建议。对于社会心理建议,AGREE-REX的分数较低。
结论:关于儿童和青少年精神分裂症的临床研究和CPG仍然很少。文件质量整体较低,建议报告的质量有很大改进。证据的质量和建议的力度也缺乏透明度。
未经评估:CRD42020164899。
The production of clinical practice
guidelines (CPGs) has grown in the past years. Notwithstanding, the quality of these documents and their recommendations for the treatment of schizophrenia in children and adolescents is still unknown.
To assess the quality of the
guidelines and recommendations for the treatment of schizophrenia in this population.
CPGs from 2004 to December 2020 were identified through a systematic search on EMBASE, MEDLINE, PsycINFO, PubMed, Epistemonikos, VHL, Global Index Medicus and specific CPG databases. The CPGs\' quality was independently assessed by three reviewers using AGREE II and they were considered of high quality if they scored ≥60% in domains 3 and 6. The evidence classification systems were described, the quality of recommendations was assessed in pairs using AGREE-REX and the recommendations were compared.
The database search retrieved 3182 results; 2030 were screened and 29 were selected for full-text reading. Four
guidelines were selected for extraction. Two CPGs were considered of high quality in the AGREE II assessment. We described the commonly agreed recommendations for each treatment phase. The pharmacological recommendations were described in all treatment phases. Scores of AGREE-REX were lower for psychosocial recommendations.
There are still few clinical studies and CPGs regarding schizophrenia in children and adolescents. The quality of the documents was overall low, and the quality of the recommendations report has much to improve. There is also a lack of transparency about the quality of the evidence and the strength of the recommendations.
CRD42020164899.